We're #hiring a new Clinical Research Coordinator in Greater Seattle Area. Apply today or share this post with your network.
SeattleNTC
Hospitals and Health Care
Seattle, WA 581 followers
When you're ready to give up, you need doctors who won't. Telehealth available!
About us
Seattle Neuropsychiatric Treatment Center (SeattleNTC) specializes in Transcranial Magnetic Stimulation (TMS), Electroconvulsive Therapy (ECT), esketamine, and other cutting-edge treatments for depression and difficult to treat neuropsychiatric disorders. We have locations in Seattle, Bellevue, Tacoma, Bellingham, and Poulsbo. We offer ECT at Swedish Ballard and Swedish Issaquah. We also offer telehealth appointments. SeattleNTC's founder, Kenneth Melman MD, was an active member of the Seattle medical and psychiatric community for more than 30 years. SeattleNTC is the oldest TMS clinic in the region and the only clinic to offer all three treatments for severe depression: TMS, ECT, and esketamine.
- Website
-
http://www.seattlentc.com
External link for SeattleNTC
- Industry
- Hospitals and Health Care
- Company size
- 11-50 employees
- Headquarters
- Seattle, WA
- Type
- Privately Held
- Founded
- 2007
- Specialties
- psychiatric treatment, treatment-refractory depression, brain stimulation, psychopharmacology, neuromodulation, transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), VNS, and research
Locations
Employees at SeattleNTC
Updates
-
This was such a good talk by Colleen Hanlon!
Physician Executive, Consultant in Innovative Psychiatric Treatments (Interventional Psychiatry), Health IT, Quality, and Practice Management
Key Clinical Takeaways from CTMSS London 2024 For Addictions Part 1 “Innovative Addiction Treatment Exploring the Global Landscape of Transcranial Magnetic Stimulation (TMS) in Substance Use Disorders” Speaker: Colleen Hanlon, PhD Addictions result from dysfunction in brain networks This leads to Impairment in response inhibition and salience attribution There are two key regulatory approvals for TMS for Addictions Europe- CE TMS for Psychostimulants (Cocaine) Target: DLPFC with Figure of Eight Coil Stimulation Protocol: 100% of MT, 10HZ 4 sec on, 15 sec off, 40 trains, 2400 pulses One session a day for five days, then 2x a day once a week for 11 weeks US- FDA TMS for Nicotine Use Disorder Target: DACC with H4 Coil Stimulation Protocol: 120% of MT, 10HZ, 3 sec on, 15 sec off, 60 trains, 1800 pulses One session a day for 15 days, then one weekly for three weeks. Can we change cue reactivity and impulsivity by targeting the mPCC? This should result in drinking days in Alcohol Use Disorder. Two studies suggest we can! Harel et al. 2021 Target: mPCC with H-7 coil Stimulation Protocol: 10HZ, 3000 pulses per session for 15 sessions Cue Prime: Yes McCalley et al. 2022 Target: mPCC with DB-60 Stimulation Protocol: 3600 Pulses, cTBS Cue Prime: Yes References https://lnkd.in/gngHKYRm https://lnkd.in/gB9bc32m https://lnkd.in/gbM7gkXf #CTMSS2024 #empathyminded #AddictionTreatment #TMS #SubstanceUseDisorder
-
-
Dear Colleagues in Mental Health, We continue to participate in a study on esmethadone for depression! Please consider referring your patients for one of our clinical trials. (1) RELIGHT is a 4-week medication trial for a novel NMDA receptor channel blocker called REL-1017 as an adjunctive treatment for MDD. The active ingredient in REL-1017 tablets is esmethadone (see: https://lnkd.in/g7XM3HkR). Patients aged 18-65 who have not responded well to 1-3 adequate antidepressant trials in the current depressive episode may qualify. Patients taking only a single antidepressant, and with minimal medical problems, are more likely to qualify. Participants are compensated for their time in the study. (2) OLO is a 2-week early access program for the SAINT TMS protocol for MDD. SAINT is different from standard TMS in two ways: 1. the brain target for the TMS is personalized based on an fMRI scan, and 2. the treatment course is 10 short treatments per day over 5 days. All patients receive the SAINT treatment (no placebo/sham), and there is a cost to participate. As this treatment requires only 2 weeks in the Seattle/Bellevue area, participants can live at any distance from our clinic (including out of state). (3) COMPASS 006 is a study on therapy-guided psilocybin for treatment of MDD, for patients who have failed to respond to 2-4 antidepressants in their current depressive episode. COMP006 involves two initial psilocybin dosing sessions spaced 3 weeks apart, followed by a 3rd and 4th dosing several months later if the participant remains depressed. Participants are randomized to one of three psilocybin doses; at the 4th dosing, all participants receive the highest dose. Participants are compensated for their time in the study. Please contact me if you have any patients who might be interested! Patients can also contact us directly at research@seattlentc.com.
-
SeattleNTC is participating in the prospective, multi-site Open-label Optimization (OLO) clinical research program to assess the effectiveness of the SAINT™ neuromodulation system to treat Major Depressive Disorder. Recruitment is active! Patients coming from a distance should expect to spend 2 weeks in the Seattle/Bellevue area -- the first week to get the fMRI, the second week to receive the treatment. OLO Study Summary: - Primary objective - to assess the effectiveness of the SAINT neuromodulation system in the treatment of MDD as measured by the Clinical Global Impression Improvement Scale (GCI-I) at the end of the treatment (cessation of stimulation). - Population - up to 1,000 adult subjects in a major depressive episode, who have failed to receive satisfactory improvement from a prior antidepressant medication in the current episode, are eligible to participate in the study if they are deemed to be appropriate candidates for transcranial magnetic stimulation (TMS). - Study duration - expected to be approximately four years, and the study duration per subject is anticipated to be approximately one year.
-
We're #hiring a new Clinical Research Program Manager in Greater Seattle Area. Apply today or share this post with your network.
-
We're #hiring a new Interventional Clinical Trials Expert in Greater Seattle Area. Apply today or share this post with your network.